The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

"Onco360 is grateful for the opportunity to partner on another therapy with the team at SpringWorks Therapeutics and become a ...

Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult ...

Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults ...

PITTSBURGH — Hundreds of people braved the cold weather and rain in just their underwear for a fundraiser in Pittsburgh.

“Just this week, we were able to have a new drug approved by the FDA called Gomekli that is actually good for both children and adults,” said Race Director Booke Bissell. About $90,000 has ...

Coming after Ogsiveo at SprongWorks is Gomekli (mirdametinib), an oral small molecule designed to inhibit MEK1 and MEK2 proteins, which has been submitted for FDA approval as a treatment for ...